Global Blood Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$23.3M
Doctors Paid
3,119
Transactions
11,164
2024 Total
$2.7M
Payment Breakdown by Category
Research$17.0M (73.0%)
Consulting$4.5M (19.4%)
Food & Beverage$166,266 (0.7%)
Travel$87,287 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.0M | 2,445 | 73.0% |
| Consulting Fee | $4.5M | 498 | 19.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $890,272 | 870 | 3.8% |
| Honoraria | $459,068 | 308 | 2.0% |
| Food and Beverage | $166,266 | 6,702 | 0.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $118,065 | 69 | 0.5% |
| Travel and Lodging | $87,287 | 269 | 0.4% |
| Grant | $50,000 | 2 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $2,780 | 1 | 0.0% |
Payments by Type
Research
$17.0M
2,445 transactions
General
$6.3M
8,719 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR | $1.7M | 0 | 146 |
| GBT_GBT_PEDIATRIC_440-007_2926_01 | $925,530 | 0 | 121 |
| A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF INCLACUMAB IN PARTICIPANTS WITH SICKLE CELL DISEASE EXPERIENCING VASOOCCLUSIVE CRISES | $858,348 | 0 | 228 |
| GBT440-4R1 | $832,236 | 0 | 39 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | $826,347 | 0 | 206 |
| AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF INCLACUMAB ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN AN INCLACUMAB CLINICAL TRIAL | $798,283 | 0 | 220 |
| Rheological Impact of GBT1118 Cessation in a Sickle Mouse Model. This study does not involve humans, only mice. | $718,661 | 0 | 1 |
| GBT_440 039_3829_01 | $717,714 | 0 | 109 |
| GBT_440-041_3939_01 | $551,648 | 0 | 120 |
| GBT_GBT440-038_3702_01 | $444,712 | 0 | 71 |
| A RETROSPECTIVE DATA COLLECTION AND ANALYSIS STUDY OF PATIENTS WITH SICKLE CELL DISEASE SCD WHO HAVE BEEN TREATED WITH OXBRYTA VOXELOTOR | $401,200 | 0 | 38 |
| GBT440-034 | $373,786 | 0 | 247 |
| AN OPEN LABEL, OBSERVATIONAL, PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE (SCD) TREATED WITH OXBRYTA (VOXELOTOR). | $312,909 | 0 | 29 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF VOXELOTOR GBT440 IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE HOPE KIDS 2 | $302,843 | 0 | 59 |
| A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY OF A SINGLE DOSE OF INCLACUMAB TO REDUCE READMISSION IN PARTICIPANTS WITH SICKLE CELL DISEASE AND RECURRENT VASOOCCLUSIVE CRISES | $293,515 | 0 | 127 |
| AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS | $292,702 | 0 | 99 |
| The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK), and pharmacodynamics (i.e., how the body absorbs, distributes, breaks down, and excretes) of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in participants with SCD, following single and multiple ascending doses. | $288,119 | 0 | 12 |
| GBT Sickle Cell Natural History | $277,465 | 0 | 10 |
| GBT440-031 | $258,926 | 0 | 89 |
| A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VOXELOTOR (GBT440) IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE | $212,127 | 4 | 46 |
| An open-label, Single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of inclacumab following intravenous infusion in healthy participants | $210,713 | 0 | 6 |
| GBT440-037 | $178,790 | 0 | 145 |
| GLOBA002_GBT440-032_80036131 | $169,099 | 0 | 27 |
| GLOBA002_GBT440-044_80046618: This is a Phase 3b, randomized, double-blind, placebo-controlled, multicenter study to assess the treatment effect of voxelotor on neurocognitive function as assessed by the National Institute of Health (NIH) Toolbox Cognition Module of executive abilities in pediatric participants (8 to < 18 years) with SCD. | $166,370 | 0 | 14 |
| GBT440-032 | $148,906 | 0 | 28 |
| AN OPENLABEL EXTENSION STUDY OF VOXELOTOR ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN VOXELOTOR CLINICAL TRIALS | $138,762 | 0 | 33 |
| AN OPEN LABEL SINGLE ARM MULTICENTER STUDY TO EVALUATE THE EFFECT OF VOXELOTOR ON CEREBRAL BLOOD FLOW AND NEUROCOGNITIVE FUNCTION IN ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE | $136,920 | 0 | 15 |
| Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays | $116,585 | 0 | 31 |
| A PHASE I OPENLABEL SINGLEDOSE NONRANDOMIZED PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF GBT021601 AN ORAL HEMOGLOBIN S POLYMERIZATION INHIBITOR IN ADULT PARTICIPANTS WITH RENAL IMPAIRMENT | $115,318 | 0 | 11 |
| A PHASE 3B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY TO EVALUATE THE TREATMENT EFFECT OF VOXELOTOR ON NEUROCOGNITIVE FUNCTION IN PEDIATRIC PARTICIPANTS 8 TO 18 YEARS OF AGE WITH SICKLE CELL DISEASE | $114,033 | 0 | 20 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Nirmish Shah, Md, MD | Internal Medicine | Durham, NC | $256,632 | $0 |
| Alan Anderson, M.d, M.D | Pediatric Hematology-Oncology | Greenville, SC | $238,675 | $0 |
| Robert Adams, Md, MD | Neurology | Charleston, SC | $225,040 | $0 |
| Biree Andemariam, Md, MD | Hematology & Oncology | Farmington, CT | $150,998 | $0 |
| Philip Pizzo, Md, MD | Pediatric Hematology-Oncology | Palo Alto, CA | $137,284 | $0 |
| Richard Drachtman | Pediatrics | New Brunswick, NJ | $115,030 | $0 |
| Caterina Minniti, Md, MD | Pediatric Hematology-Oncology | Washington, DC | $102,742 | $0 |
| Santosh Saraf, M.d, M.D | Hematology & Oncology | Chicago, IL | $95,966 | $0 |
| Dr. William Ershler, M.d, M.D | Hematology & Oncology | Fairfax, VA | $78,583 | $0 |
| Alexis Thompson, Md, MD | Pediatric Hematology-Oncology | Chicago, IL | $77,061 | $0 |
| Charles Homcy, M.d, M.D | General Acute Care Hospital | San Francisco, CA | $72,500 | $0 |
| Ahmar Zaidi, M.d, M.D | Pediatrics | Detroit, MI | $67,918 | $0 |
| Brett Giroir, Md, MD | Pediatric Critical Care Medicine | Dallas, TX | $64,296 | $0 |
| Wanda Whitten-Shurney, Md, MD | Pediatrics | Detroit, MI | $55,722 | $0 |
| Patricia Adams-Graves, Md, MD | Internal Medicine | Memphis, TN | $44,133 | $0 |
| Robert Brown, Md, Phd, MD, PHD | Hematology & Oncology | Atlanta, GA | $41,384 | $0 |
| Ifeyinwa Osunkwo, Md, MD | Pediatrics | Charlotte, NC | $38,964 | $0 |
| Jawan Ayer, Md, MD | Obesity Medicine | Tampa, FL | $36,249 | $0 |
| Kusum Viswanathan, M.d, M.D | Pediatric Hematology-Oncology | Brooklyn, NY | $34,078 | $0 |
| Dr. Wally Smith, M.d, M.D | Internal Medicine | Richmond, VA | $33,509 | $0 |
| Dr. Alex George, M.d., Ph.d, M.D., PH.D | Pediatric Hematology-Oncology | Winston Salem, NC | $32,850 | $0 |
| Dr. Zahra Pakbaz, Md, MD | Hematology | Orange, CA | $32,340 | $0 |
| Dr. Joseph Betancourt, Md, MD | Internal Medicine | Boston, MA | $31,473 | $0 |
| Elliott Vichinsky, Md, MD | Pediatric Hematology-Oncology | Oakland, CA | $29,259 | $0 |
| Dr. Jeremie Estepp, Md, MD | Pediatrics | Memphis, TN | $28,546 | $0 |
About Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. has made $23.3M in payments to 3,119 healthcare providers, recorded across 11,164 transactions in the CMS Open Payments database. In 2024, the company paid $2.7M. The top product by payment volume is OXBRYTA ($17.8M).
Payments were distributed across 99 medical specialties. The top specialty by payment amount is Pediatric Hematology-Oncology ($1.1M to 154 doctors).
Payment categories include: Food & Beverage ($166,266), Consulting ($4.5M), Research ($17.0M), Travel & Lodging ($87,287).
Global Blood Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.